Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC
Shots:
- The US FDA has granted approval to Rybrevant in addition to SoC CT (carboplatin and pemetrexed) for treating EGFR-mutated (exon 19 deletions/L858R substitution mutations) locally advanced or metastatic NSCLC in adults whose disease progressed on or after EGFR TKI
- The approval was supported by P-III (MARIPOSA-2) trial assessing the safety & efficacy of Rybrevant (with/without Lazcluze) + CT vs CT alone for treating EGFR-mutated NSCLC patients (n=657), progressed on or after osimertinib
- Study depicted a PFS (1EP) of 52% with an mPFS of 6.3mos. vs 4.2mos. and confirmed ORR of 53% vs 29% with the combination vs CT alone
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related Post:- Johnson & Johnson Reports the US FDA’s Approval of Rybrevant + Lazcluze as a 1L Treatment of NSCLC with EGFR Mutations
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
